Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN JOHN LEBERTHON

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1326023979
CMS profile
241091
Location
WEST COVINA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,220.50

251 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,968.85 248
Long term medical supply or device loan $166.66 2
Education $84.99 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $794.66 21
Incyte Corporation $495.02 15
NOVARTIS PHARMACEUTICALS CORPORATION $479.88 19
E.R. Squibb & Sons, L.L.C. $321.38 20
Foundation Medicine, Inc. $297.49 8
Karyopharm Therapeutics Inc. $297.32 9
Gilead Sciences, Inc. $287.47 15
GENZYME CORPORATION $283.61 11
Daiichi Sankyo Inc. $242.19 14
PFIZER INC. $237.99 12
Amgen Inc. $220.10 11
Puma Biotechnology, Inc. $195.33 7
Seagen Inc. $194.81 4
Takeda Pharmaceuticals U.S.A., Inc. $166.92 7
Celgene Corporation $165.93 8
Merck Sharp & Dohme LLC $142.38 7
Genentech USA, Inc. $137.19 9
Pharmacyclics LLC, An AbbVie Company $130.50 4
Immunocore Limited $97.31 1
Mirati Therapeutics, Inc. $83.89 4
Dendreon Pharmaceuticals LLC $71.30 3
Acrotech Biopharma Inc. $68.11 3
Sumitomo Pharma America, Inc. $62.43 4
ABBVIE INC. $56.06 3
TAIHO ONCOLOGY, INC. $54.35 2
Alexion Pharmaceuticals, Inc. $52.57 3
ImmunoGen, Inc. $50.12 3
PharmaEssentia USA Corporation $48.36 2
Agios Pharmaceuticals, Inc. $47.16 2
Bayer Healthcare Pharmaceuticals Inc. $42.01 2
Rigel Pharmaceuticals, Inc. $30.03 1
Genmab U.S., Inc. $29.96 1
EMD Serono, Inc. $28.88 1
Janssen Biotech, Inc. $26.15 1
BeiGene USA, Inc. $25.95 1
GlaxoSmithKline, LLC. $24.05 1
ADC Therapeutics America, Inc. $23.64 1
Astellas Pharma US Inc $23.50 1
AVEO Pharmaceuticals, Inc. $22.18 1
ARRAY BIOPHARMA INC $21.59 1
Eisai Inc. $20.72 1
Novocure Inc. $19.47 1
Coherus Biosciences Inc. $18.61 1
Stemline Therapeutics Inc. $18.18 1
MorphoSys, US Inc. $17.81 1
Alnylam Pharmaceuticals Inc. $16.84 1
Lilly USA, LLC $15.90 1
Kite Pharma, Inc. $13.20 1

Page 5 of 6; records 201–250 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN JOHN LEBERTHON

NPI 1326023979 · CMS profile ID 241091

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WEST COVINA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326023979?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN JOHN LEBERTHON, NPI 1326023979, CMS profile ID 241091. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326023979?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BRIAN JOHN LEBERTHON, NPI 1326023979, CMS profile ID 241091. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326023979?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BRIAN JOHN LEBERTHON, NPI 1326023979, CMS profile ID 241091, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1326023979?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

251 matching records · $6,220.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 251 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 251.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $1.6903/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840875 CMS
Amgen Inc. $15.6003/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840879 CMS
Novartis Pharmaceuticals Corporation $21.0103/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992159901 CMS
Alnylam Pharmaceuticals Inc. $16.8403/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006122653 CMS
Gilead Sciences, Inc. $13.2003/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026041555 CMS
Karyopharm Therapeutics Inc. $14.4803/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898035 CMS
Karyopharm Therapeutics Inc. $0.2803/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898039 CMS
Karyopharm Therapeutics Inc. $0.5003/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898043 CMS
BeiGene USA, Inc. $25.9503/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051195183 CMS
E.R. Squibb & Sons, L.L.C. $16.3202/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015231339 CMS
Incyte Corporation $24.5102/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044477671 CMS
Seagen Inc. $125.0002/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995713337 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.6302/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055448923 CMS
E.R. Squibb & Sons, L.L.C. $14.9402/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015231363 CMS
Incyte Corporation $125.0002/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044477679 CMS
Gilead Sciences, Inc. $16.6002/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025943207 CMS
Celgene Corporation $0.5402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015231347 CMS
Celgene Corporation $24.6502/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015231355 CMS
Daiichi Sankyo Inc. $28.9002/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006398845 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $83.3302/15/2023 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993431833 CMS
GlaxoSmithKline, LLC. $24.0502/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003296927 CMS
ABBVIE INC. $24.6902/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997737957 CMS
Incyte Corporation $13.4502/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044477657 CMS
AstraZeneca Pharmaceuticals LP $124.9802/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011359715 CMS
Acrotech Biopharma Inc. $21.9202/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052991675 CMS
Gilead Sciences, Inc. $22.6002/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025721517 CMS
Mirati Therapeutics, Inc. $19.9402/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057996005 CMS
GENZYME CORPORATION $23.7202/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049803904 CMS
Karyopharm Therapeutics Inc. $1.2902/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898027 CMS
Karyopharm Therapeutics Inc. $22.5802/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898031 CMS
Pharmacyclics LLC, An AbbVie Company $32.6202/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998289501 CMS
PharmaEssentia USA Corporation $22.0001/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059313447 CMS
AstraZeneca Pharmaceuticals LP $19.8301/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011280798 CMS
AstraZeneca Pharmaceuticals LP $18.0101/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014343073 CMS
Celgene Corporation $32.7101/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015231299 CMS
Eisai Inc. $20.7201/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023304259 CMS
E.R. Squibb & Sons, L.L.C. $21.7701/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015231293 CMS
ADC Therapeutics America, Inc. $23.6401/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053800713 CMS
Merck Sharp & Dohme LLC $13.0301/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048688805 CMS
Genentech USA, Inc. $22.0301/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040317021 CMS
Genentech USA, Inc. $1.4401/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040317039 CMS
Karyopharm Therapeutics Inc. $120.0001/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898047 CMS
Karyopharm Therapeutics Inc. $120.0001/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898051 CMS
Daiichi Sankyo Inc. $21.2001/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006380741 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $83.3301/14/2023 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993431831 CMS
Incyte Corporation $24.5901/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044477641 CMS
Novartis Pharmaceuticals Corporation $11.7501/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992159892 CMS
GENZYME CORPORATION $22.9701/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049803873 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.6801/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055448917 CMS
Celgene Corporation $23.1401/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015231285 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,277.41 229
PY2020 $3,717.37 181
PY2021 $4,875.82 247
PY2022 $5,705.56 251
PY2023 $6,220.50 251
PY2024 $6,010.66 235
PY2025 $6,217.64 261

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $21,474.68 2
PY2023 Principal investigator $10,724.22 4
PY2022 Principal investigator $112,114.20 10
PY2021 Principal investigator $55,090.80 10
PY2020 Principal investigator $189,386.37 22
PY2019 Principal investigator $82,199.26 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

2 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $13,834.68 09/12/2024 Non-covered Recipient Entity
Brian J Leberthon, Md A Medical Corpration
BAY 806946, A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkins lymphoma (iNHL) No dispute reported 06/30/2026 1085979058
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $7,640.00 01/16/2024 Non-covered Recipient Entity
Brian J Leberthon, Md A Medical Corpration
BAY 806946, A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkins lymphoma (iNHL) No dispute reported 06/30/2026 1085979060